up to now few years, the UK has witnessed a revolution in health-related excess weight‑reduction treatments — with the introduction of semaglutide (Wegovy®) to the escalating reputation of tirzepatide (Mounjaro®). Now, A further name is drawing focus in the two scientific and general public overa